Medroxyprogesterone instructions for administration: Difference between revisions
No edit summary |
Matt Pijoan (talk | contribs) m (Reverted edits by Puwok2008mlA7 (talk) to last revision by NNethala) |
||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
== | ==Instructions for administration== | ||
<font size="4">[[Alprazolam overdose#Vasomotor Symptoms / Vulvar and Vaginal Atrophy|Vasomotor Symptoms / Vulvar and Vaginal Atrophy]]</font> | <font size="4">[[Alprazolam overdose#Vasomotor Symptoms / Vulvar and Vaginal Atrophy|Vasomotor Symptoms / Vulvar and Vaginal Atrophy]]</font> | ||
<br> | <br> | ||
| Line 13: | Line 13: | ||
individual patient response. In patients where bleeding or spotting remains a problem, after appropriate | individual patient response. In patients where bleeding or spotting remains a problem, after appropriate | ||
evaluation, consideration should be given to changing the dose level. This dose should be periodically | evaluation, consideration should be given to changing the dose level. This dose should be periodically | ||
reassessed by the healthcare provider. | reassessed by the healthcare provider. ''[[Medroxyprogesterone instructions for administration#Instructions for administration|Return to top]]'' | ||
<br> | <br> | ||
===Postmenopausal Osteoporosis=== | ===Postmenopausal Osteoporosis=== | ||
| Line 25: | Line 24: | ||
PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken | PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken | ||
daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and | daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and | ||
5 mg of medroxyprogesterone acetate, taken on days 15 through 28. | 5 mg of medroxyprogesterone acetate, taken on days 15 through 28. ''[[Medroxyprogesterone instructions for administration#Instructions for administration|Return to top]]'' | ||
<br> | <br> | ||
<br> | <br> | ||
Latest revision as of 14:40, 20 December 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Instructions for administration
Vasomotor Symptoms / Vulvar and Vaginal Atrophy
Postmenopausal Osteoporosis
Vasomotor Symptoms / Vulvar and Vaginal Atrophy
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Subsequent dosage adjustment may be made based upon the
individual patient response. In patients where bleeding or spotting remains a problem, after appropriate
evaluation, consideration should be given to changing the dose level. This dose should be periodically
reassessed by the healthcare provider. Return to top
Postmenopausal Osteoporosis
Patients should be treated with the lowest effective dose. Generally women should be started at
0.3 mg/1.5 mg PREMPRO daily. Dosage may be adjusted depending on individual clinical and bone
mineral density responses. This dose should be periodically reassessed by the healthcare provider.
In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration
should be given to changing the dose level. This dose should be periodically reassessed by the
healthcare provider.
PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken
daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and
5 mg of medroxyprogesterone acetate, taken on days 15 through 28. Return to top
Adapted from the FDA Package Insert.